In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma

This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2022-12, Vol.27 (12), p.e977-e978
Hauptverfasser:	Osanto, Susanne, Woei-A-Jin, F J Sherida H, Coenraad, Minneke J, Weijl, Nir I, Burgmans, Mark C, Burggraaf, Jacobus
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma, Hepatocellular - drug therapy Humans Letter to the Editor Liver Neoplasms - drug therapy Neoadjuvant Therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma.
ISSN:	1083-7159 1549-490X
DOI:	10.1093/oncolo/oyac215